mage-3.1 antigen
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1997 (NCT00002952)
Timeline
Indications
Studied for
Mechanism of action
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mage-3.1 antigen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01307618 | Phase 2 | Feb 1, 2011 | National Cancer Institute (NCI), University of Chicago |
| NCT00085189 | Phase 2 | May 1, 2004 | National Cancer Institute (NCI), University of Southern California |
| NCT00003792 | Phase 1 | Apr 1, 1999 | Baylor University, National Cancer Institute (NCI) |
| NCT00002952 | Phase 1/Phase 2 (Phase 2) | Jan 1, 1997 | National Cancer Institute (NCI), University of Chicago |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 4 | 1 | 2 | 1997 |
| University of Chicago | Academic/Hospital | 2 | 1 | 1 | 1997 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2004 |
4 organizations
Page 1 / 1